LCM
PTGX icon

Lynx1 Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Lynx1 Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-700,014
Closed -$46.5M – 27
2025
Q3 		$46.5M Sell
700,014
-33,000
-5% -$1.88M 9.47% 4
2025
Q2 		$40.5M Hold
733,014
– – 11.7% 4
2025
Q1 		$35.4M Buy
+733,014
New +$30.7M 12.69% 3

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lynx1 Capital Management's PTGX Position: Q4 2025 in Review

Lynx1 Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 700,014 shares — an estimated $46.5M sold.

Lynx1 Capital Management first reported a position in PTGX in Q1 2025 and held it in 3 quarters. The position peaked at $46.5M in Q3 2025. 314 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Lynx1 Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 700,014 Protagonist Therapeutics shares in Q4 2025, an estimated $46.5M.
  • Lynx1 Capital Management first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 3 quarters.
  • Lynx1 Capital Management's Protagonist Therapeutics position peaked at $46.5M in Q3 2025.
  • 314 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Lynx1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.